AdCom Approval, Reservations on Praluent Largely Inline with Expectations; Roth Affirms Regeneron (REGN) at 'Neutral'

June 10, 2015 7:54 AM

Roth capital affirms Regeneron Pharmaceuticals (Nasdaq: REGN) with a Neutral rating and $495 price target after the company confirmed that ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found